Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL)
CUSIP: 137404109
Q2 2023 13F Holders as of 30 Jun 2023
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 72,977,477
- Total 13F shares
- 5,370,044
- Share change
- -108,224
- Total reported value
- $6,766,125
- Price per share
- $1.26
- Number of holders
- 19
- Value change
- -$142,743
- Number of buys
- 5
- Number of sells
- 8
Quarterly Holders Quick Answers
What is CUSIP 137404109?
CUSIP 137404109 identifies CADL - Candel Therapeutics, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 137404109:
Top shareholders of CADL - Candel Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Laura K. Aguilar |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,046,940
|
$2,742,246 | — | 06 May 2022 | |
| Northpond Ventures, LLC |
13F
|
Company |
2.7%
|
1,935,215
|
$2,612,540 | — | 31 Mar 2023 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.5%
|
1,125,000
|
$1,541,250 | — | 31 Mar 2023 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
1.1%
|
811,737
|
$1,095,845 | — | 31 Mar 2023 | |
| FMR LLC |
13F
|
Company |
0.84%
|
613,157
|
$840,025 | — | 31 Mar 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.56%
|
405,755
|
$547,769 | — | 31 Mar 2023 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.18%
|
132,700
|
$181,799 | — | 31 Mar 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.18%
|
131,203
|
$179,748 | — | 31 Mar 2023 | |
| Baystate Wealth Management LLC |
13F
|
Company |
0.15%
|
105,854
|
$142,903 | — | 31 Mar 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.06%
|
47,174
|
$64,628 | — | 31 Mar 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.06%
|
46,544
|
$62,835 | — | 31 Mar 2023 | |
| Udi Meirav |
3/4/5
|
Director |
—
class O/S missing
|
48,822
|
$43,940 | — | 26 Jul 2021 | |
| STATE STREET CORP |
13F
|
Company |
0.04%
|
27,600
|
$37,812 | — | 31 Mar 2023 | |
| OneDigital Investment Advisors LLC |
13F
|
Company |
0.03%
|
25,428
|
$34,328 | — | 31 Mar 2023 | |
| SMITH ALAN E |
3/4/5
|
Director |
—
class O/S missing
|
32,548
|
$29,293 | — | 26 Jul 2021 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.03%
|
21,000
|
$28,000 | — | 31 Mar 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.03%
|
19,617
|
$26,483 | — | 31 Mar 2023 | |
| Empirical Asset Management, LLC |
13F
|
Company |
0.02%
|
12,000
|
$16,200 | — | 31 Mar 2023 | |
| Ergoteles LLC |
13F
|
Company |
0.02%
|
11,416
|
$15,640 | — | 31 Mar 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
6,576
|
$9,000 | — | 31 Mar 2023 | |
| Nathan Caffo |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
6,000
|
$5,400 | — | 29 Jul 2021 | |
| Quent Capital, LLC |
13F
|
Company |
0%
|
182
|
$246 | — | 31 Mar 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
100
|
$135 | — | 31 Mar 2023 | |
| UBS Group AG |
13F
|
Company |
0%
|
10
|
$14 | — | 31 Mar 2023 | |
| John J. Canepa |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
110,000
|
— | — | 28 Feb 2022 | |
| Susan B. Stewart |
3/4/5
|
Chief Regulatory Officer |
—
class O/S missing
|
20,000
|
— | — | 11 Apr 2022 |
Institutional Holders of Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL) as of Q2 2023
As of 30 Jun 2023,
Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,370,044 shares.
The largest 10 holders included
Northpond Ventures, LLC, FRANKLIN RESOURCES INC, Sands Capital Ventures, LLC, FMR LLC, VANGUARD GROUP INC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, GEODE CAPITAL MANAGEMENT, LLC, CITIGROUP INC, Baystate Wealth Management LLC, and BlackRock Inc..
This page lists
19
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
20
Q2 2023 holders
19
Holder diff
-1
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 Value $ | Q2 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.